Print this page    •   Back to Web version of article

Limited T-20 Compassionate Use Program Launches in October

September/October 2002

Individuals with HIV who are in need of a salvage therapy and who meet certain criteria may be able to access T-20, also known as Fuzeon, through a compassionate use program expected to begin in October.

T-20, a member of a new class of drugs called fusion inhibitors, is administered by injection twice a day. FDA approval of the drug is expected soon.

Only 600 slots in the program are available. Individuals enrolling in the program must be 6 years old or older, have a viral load greater than 10,000 copies and a CD4 count of less than 100 cells/mm3 while on highly active antiretroviral therapy. Individuals must also "be limited by the currently commercial available antiretroviral agents as per the judgment of the investigator," according to a letter announcing the program.

Individuals interested in the program should consult their physicians.

Back to the September/October 2002 issue of Positive Living.

This article has been reprinted at The Body with the permission of AIDS Project Los Angeles (APLA).

This article was provided by AIDS Project Los Angeles. It is a part of the publication Positive Living. You can find this article online by typing this address into your Web browser:

General Disclaimer: is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.